PortfoliosLab logoPortfoliosLab logo
ACRV vs. HURA
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

ACRV vs. HURA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Acrivon Therapeutics Inc. Common Stock (ACRV) and TuHURA Biosciences, Inc. (HURA). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

ACRV vs. HURA - Yearly Performance Comparison


2026 (YTD)2025202420232022
ACRV
Acrivon Therapeutics Inc. Common Stock
-42.32%-59.97%22.36%-57.29%-30.77%
HURA
TuHURA Biosciences, Inc.
136.55%-81.50%-31.10%-97.54%73.12%

Fundamentals

EPS

ACRV:

-$2.02

HURA:

-$0.62

Total Revenue (TTM)

ACRV:

$0.00

HURA:

$0.00

Gross Profit (TTM)

ACRV:

$0.00

HURA:

-$17.64K

EBITDA (TTM)

ACRV:

-$84.11M

HURA:

-$28.68M

Returns By Period

In the year-to-date period, ACRV achieves a -42.32% return, which is significantly lower than HURA's 136.55% return.


ACRV

1D
7.75%
1M
-7.95%
YTD
-42.32%
6M
-23.20%
1Y
-31.53%
3Y*
-52.15%
5Y*
10Y*

HURA

1D
3.47%
1M
7.19%
YTD
136.55%
6M
-27.82%
1Y
-44.58%
3Y*
-75.62%
5Y*
-77.66%
10Y*
-65.23%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ACRV vs. HURA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ACRV
ACRV Risk / Return Rank: 2828
Overall Rank
ACRV Sharpe Ratio Rank: 2828
Sharpe Ratio Rank
ACRV Sortino Ratio Rank: 3636
Sortino Ratio Rank
ACRV Omega Ratio Rank: 3535
Omega Ratio Rank
ACRV Calmar Ratio Rank: 1919
Calmar Ratio Rank
ACRV Martin Ratio Rank: 2020
Martin Ratio Rank

HURA
HURA Risk / Return Rank: 2929
Overall Rank
HURA Sharpe Ratio Rank: 2525
Sharpe Ratio Rank
HURA Sortino Ratio Rank: 3636
Sortino Ratio Rank
HURA Omega Ratio Rank: 3535
Omega Ratio Rank
HURA Calmar Ratio Rank: 2424
Calmar Ratio Rank
HURA Martin Ratio Rank: 2525
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ACRV vs. HURA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Acrivon Therapeutics Inc. Common Stock (ACRV) and TuHURA Biosciences, Inc. (HURA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ACRVHURADifference

Sharpe ratio

Return per unit of total volatility

-0.29

-0.35

+0.05

Sortino ratio

Return per unit of downside risk

0.27

0.24

+0.03

Omega ratio

Gain probability vs. loss probability

1.03

1.03

+0.01

Calmar ratio

Return relative to maximum drawdown

-0.66

-0.55

-0.11

Martin ratio

Return relative to average drawdown

-1.12

-0.97

-0.16

ACRV vs. HURA - Sharpe Ratio Comparison

The current ACRV Sharpe Ratio is -0.29, which is comparable to the HURA Sharpe Ratio of -0.35. The chart below compares the historical Sharpe Ratios of ACRV and HURA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


ACRVHURADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.29

-0.35

+0.05

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.56

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.51

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.50

-0.46

-0.04

Correlation

The correlation between ACRV and HURA is 0.09, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

ACRV vs. HURA - Dividend Comparison

Neither ACRV nor HURA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ACRV vs. HURA - Drawdown Comparison

The maximum ACRV drawdown since its inception was -95.47%, roughly equal to the maximum HURA drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for ACRV and HURA.


Loading graphics...

Drawdown Indicators


ACRVHURADifference

Max Drawdown

Largest peak-to-trough decline

-95.47%

-100.00%

+4.53%

Max Drawdown (1Y)

Largest decline over 1 year

-57.14%

-89.60%

+32.46%

Max Drawdown (5Y)

Largest decline over 5 years

-99.99%

Max Drawdown (10Y)

Largest decline over 10 years

-100.00%

Current Drawdown

Current decline from peak

-94.01%

-100.00%

+5.99%

Average Drawdown

Average peak-to-trough decline

-69.27%

-88.16%

+18.89%

Ulcer Index

Depth and duration of drawdowns from previous peaks

33.81%

50.98%

-17.17%

Volatility

ACRV vs. HURA - Volatility Comparison

The current volatility for Acrivon Therapeutics Inc. Common Stock (ACRV) is 19.87%, while TuHURA Biosciences, Inc. (HURA) has a volatility of 28.24%. This indicates that ACRV experiences smaller price fluctuations and is considered to be less risky than HURA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


ACRVHURADifference

Volatility (1M)

Calculated over the trailing 1-month period

19.87%

28.24%

-8.37%

Volatility (6M)

Calculated over the trailing 6-month period

75.44%

105.26%

-29.82%

Volatility (1Y)

Calculated over the trailing 1-year period

108.07%

128.59%

-20.52%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

105.27%

139.29%

-34.02%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

105.27%

127.70%

-22.43%

Financials

ACRV vs. HURA - Financials Comparison

This section allows you to compare key financial metrics between Acrivon Therapeutics Inc. Common Stock and TuHURA Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober00
(ACRV) Total Revenue
(HURA) Total Revenue
Values in USD except per share items